Duke University Health System
Durham, North Carolina, 27710, United States
NCT Number: NCT03139877
Using an observational case-control cohort design, the investigator aims to define the mechanisms underlying microbiome regulation of metabolism in adolescence before and after medically indicated therapies for obesity. The investigator's overarching hypothesis is that gut bacteria control host weight, insulin sensitivity, and response to weight-loss treatments by modifying host metabolism.
Looking for future studies?
Notify Me10 year–18 year
All sexes
Observational
Durham, North Carolina, 27710, United States
Intervention Cohorts: A prospective, longitudinal observational case control study will be performed. All subjects will receive Healthy Lifestyle Program (HLP) standard of care, which includes intensive lifestyle modification and free participation in Bull City Fit. Four groups of participants receiving obesity treatment will be enrolled: (1) HLP-only, (2) HLP + Low carbohydrate diet, (3) HLP + weight loss medication(s) and (4) HLP + Bariatric surgery. Consistent with the observational design of this study, study participants will be assigned to each group as per usual HLP clinical care, based on established standards and guidelines, expert medical provider recommendations, and family preference.
Comparison Cohort: two comparison groups be enrolled:(1c) healthy siblings of enrolled intervention subjects and (2c) age/sex matched controls recruited from the Duke Children's Primary Care Clinic.
Up to 350 participants will be enrolled, with the goal of 295 evaluable participant data. The study period is six months for all groups with the exception of the bariatric surgery group which will last from baseline until after surgery, up to 12 months. The comparison groups will have one visit at baseline only.
Stool Sample Collection: Participants in both intervention and comparison groups will provide a fecal sample at enrollment or within 3 days of enrollment. Participants in intervention groups (Groups 1-4) will provide additional fecal samples at 1.5, 3, 4.5, and 6 months. Given that the ability to collect fecal samples is unpredictable, the investigator will develop a standard operating procedure along the following guidelines:
Plasma sample collection: Participants in intervention groups will provide a 20mL blood samples at baseline, 3 and 6 months at the time of a regular HLP visit. The standard HLP clinical protocol is to draw fasting labs at baseline and 6 months, so no additional blood draws beyond what is required for clinical care will be required at those visits. However, HLP patients do not typically have a blood draw at 3 months, so participants will be asked for a blood sample at 3 months they would not otherwise require. Participants in comparison groups (Groups 1c, 2c) will be asked for a blood sample at enrollment only; they would not otherwise require this sample.
Analysis of samples: Fecal samples will be analyzed for the composition of the microbiota using DNA sequencing methods. Specific bacteria associated with obesity will be isolated from fecal samples and studied in the laboratory for their metabolism. A subset of fecal samples will be transferred into the intestinal tracts of germ free mice to study the effects on their metabolism. Participant plasma will be analyzed for panels of metabolites that are associated with diabetes mellitus and obesity. Blood mononuclear cell DNA will be used for focused genetic testing to identify genetic changes associated with obesity.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Baseline and 6 months
We will measure weight (in kilograms) and height (in cm) for all subjects at baseline and at 6 months (12 months for the surgery group). The between-group difference in Body Mass Index change will be reported.
Time frame: Baseline and 6 months
Blood pressure will be measured at baseline and 6-months (12-months for the surgery group) using standard methods, and change in blood pressure between groups will be reported
Time frame: Baseline and 6 months
We will perform a 3-minute standardized stepping test at baseline and 6-months (12 months for surgery group) and compare between-group differences in heart rate change with step test.
Time frame: Baseline and 6 months
We will measure fasting blood cholesterol at baseline and at 6-months (12 months for surgery group) and compare between-group differences in total cholesterol.
Time frame: Baseline and 6 months
We will measure fasting blood glucose at baseline and at 6-months (12 months for surgery group) and compare between-group differences in fasting blood glucose.
Time frame: Baseline and every 6 weeks up to 6 months (0m, 1.5m, 3m, 4.5m, 6m)
Fecal samples will be analyzed for the composition of the microbiota by extracting and sequencing the RNA from the organisms. We will report the communities of microbes at each time point.
Time frame: Baseline, 3 months and 6 months
Blood samples will be analyzed for a panel of metabolites that may be produced by the intestinal microbiota. We will report the metabolic profiles at each time point.
Duke University
Other
Pediatric Obesity Observational Prospective Trial: Microbiome and Metabolism During Obesity Target Therapeutics
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06085040
Body Weight, Nutrition Disorders
Clermont-Ferrand, France
View Trial DetailsNCT06548074
Behavior, Body Weight
Las Cruces, New Mexico, United States
View Trial DetailsNCT06981429
Body Weight, Nutrition Disorder
Buffalo, New York, United States
View Trial DetailsNCT06357299
Body Weight, Body Weight Changes
Durham, North Carolina, United States
View Trial Details